Sanofi SA (SASY)

Frankfurt
Currency in EUR
83.04
+0.12(+0.14%)
Delayed Data·
SASY Scorecard
Full Analysis
Has raised its dividend for 26 consecutive years
High dividend Yield
Fair Value
Day's Range
82.9085.00
52 wk Range
82.50110.02
Key Statistics
Edit
Bid/Ask
82.92 / 83.03
Prev. Close
82.92
Open
85
Day's Range
82.9-85
52 wk Range
82.5-110.02
Volume
700
Average Volume (3m)
1.2K
1-Year Change
-6.11%
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
SASY Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Analysts Sentiment
Currently not supported.
Members' Sentiments
Bearish
Bullish
ProTips
4 analysts have revised their earnings downwards for the upcoming period

Sanofi SA News & Analysis

Show more

Sanofi SA Company Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. The company provides immunology and inflammation, rare diseases, neurology, oncology, and other medicines and vaccines. It also offers poliomyelitis, pertussis, and haemophilus influenzae type b (Hib) pediatric vaccines; respiratory syncytial virus protection and hexavalent combination vaccines protecting against diphtheria, tetanus, pertussis, polio, Hib, and hepatitis B; influenza, booster, meningitis, and travel and endemic vaccines, which includes hepatitis A, typhoid, yellow fever, and rabies vaccines. In addition, the company has a collaboration and license agreement with Exscientia to develop up to 15 novel small-molecule for oncology and immunology; ABL Bio, Inc. to develop ABL301, a treatment for alpha-synucleinopathies; Innate Pharma SA for a natural killer cell engager program targeting B7-H3; and Blackstone Life Sciences to develop pivotal studies and clinical development program. Further, it has a collaboration agreement with IGM Biosciences, Inc. to develop, manufacture, and commercialize IgM antibody; Kymera Therapeutics, Inc. to develop and commercialize protein degrader therapies targeting IRAK4 in patients with immune-inflammatory diseases; Nurix Therapeutics, Inc. to develop novel targeted protein degradation therapies; Denali Therapeutics Inc. to treat a range of systemic inflammatory diseases, such as ulcerative colitis; and Adagene Inc. for the discovery and development of antibody-based therapies. Additionally, it has a collaboration with Scribe Therapeutics Inc. to develop genome editing technologies; and co-promotion service agreement with Provention Bio, Inc. for the commercialization of teplizumab, as well as an strategic alliance with the Department of Health – Abu Dhabi for the development of global vaccines. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was incorporated in 1994 and is headquartered in Paris, France.

Employees
82878
Market
Germany

Compare SASY to Peers and Sector

Metrics to compare
SASY
Peers
Sector
Relationship
P/E Ratio
16.3x12.9x−0.5x
PEG Ratio
0.410.090.00
Price/Book
1.3x1.6x2.6x
Price / LTM Sales
2.2x2.0x3.0x
Upside (Analyst Target)
-20.0%52.6%
Fair Value Upside
Unlock12.3%8.7%Unlock

Dividends

Payout Ratio
Payout ratio (TTM)
Earnings retained
EPS 4.98%
Dividend Yield
4.73%
Industry Median 1.49%
Annualised payout
3.92
Paid annually
5-Years Growth
-
Growth Streak

Earnings

Latest Release
Apr 24, 2025
EPS / Forecast
1.38 / 1.69
Revenue / Forecast
10.61B / 10.23B
EPS Revisions
Last 90 days

People Also Watch

1,733.500
RHMG
-1.37%
298.94
UNH
-1.02%
47.01
SOGN
-1.45%
246.60
TCFP
-1.12%
359.00
OREP
-1.63%

FAQ

What Is the Sanofi SA (SASY) Share Price Today?

The live Sanofi SA share price today is 83.04.

What Stock Exchange Does Sanofi SA (SASY) Trade On?

Sanofi SA is listed and trades on the Frankfurt Stock Exchange stock exchange.

What Is the Ticker (Stock Symbol) for Sanofi SA?

The stock symbol (also called a 'ticker') for Sanofi SA is "SASY."

Does Sanofi SA Pay Dividends? What’s The Current SASY Dividend Yield?

Yes, SASY Pays Dividends to its Shareholders. The current Sanofi SA dividend yield is 4.73%.

What Is the Current Sanofi SA Market Cap?

As of today, Sanofi SA market capitalisation is 101.44B.

What Is Sanofi SA's (SASY) Earnings Per Share (TTM)?

The Sanofi SA EPS 4.98 (Trailing Twelve Months).

When Is the Next Sanofi SA Earnings Date?

Sanofi SA's next earnings report will be released on 30 Jul 2025.

Is SASY a Buy or Sell From a Technical Analyst Perspective?

Based on today's Sanofi SA moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.

How Many Times Has Sanofi SA Stock Split?

Sanofi SA has split 0 times. (See the SASY stock split history page for full effective split date and price information.)

How Many Employees Does Sanofi SA Have?

Sanofi SA currently has 82878 employees.

What is the current trading status of Sanofi SA (SASY)?

As of 23 Jun 2025, Sanofi SA (SASY) is trading at a price of 83.04, with a previous close of 82.92. The stock has fluctuated within a day range of 82.90 to 85.00, while its 52-week range spans from 82.50 to 110.02.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.